Hester Biosciences reported standalone revenue growth of 28% in Q2 and PAT growth of 131%; consolidated revenue rose 38%, while H1 standalone revenue increased 21% and PAT 108%.

4 source passages

take you through Hester Biosciences performance for the second quarter and first half of financial year '27 standalone revenue increased by 28% in Q2 and 21% in H1 over the corresponding period of the previous year. PAT, which more than doubled, increasing by 131% during the quarter, and 108% in the first half. revenue grew by 38% in Q2 and 13% in H1, primarily driven by the India business. Open the document at this passage

Jul 30

Earnings call

Q1 2027 earnings call AI summary on its way

May 15

Earnings call

Q4 2026 earnings call AI summary on its way

Jan 30

Earnings call

Q3 2026 earnings call AI summary on its way

Showing 1–4 of 4 documents